Biotek-snakken — Maj 2024
-
Deres PharmaShell teknologi kunne være godt bud på Long acting injectables for en række lægemidler. Har projekt med liraglutid. Desuden muligt partnerskab med Novo Nordisk, mon ikke glp1/sema, men undisclosed Her ligger upside især og Novo skal snart beslutte, om de vil indgå licensaftale. Lav marketcap., høj
risiko, stor upside. -
Calliditas Therapeutics - Calliditas Q1 report, January – March 2024:
Calliditas Therapeutics AB
Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas Therapeutics AB (www.calliditas.se)
-
Target market expansion following full approval in the US
Net sales amounted to SEK 295.5 million, of which TARPEYO
net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the three months ended March 31, 2023, net sales amounted to SEK 191.4 million, of which TARPEYO net sales amounted to SEK 185.7 million. -
-
STENOCARE lancerer næste generation af medicinsk cannabisolie i Australien - seks måneder før planlagt https://proinvestor.com/boards/120588
-
Calliditas Q1: A powerful Tarpeyo launch momentum
RESEARCH UPDATE 2024-05-24
(Redeye)
"Base Case: SEK 285 (270) per share"
-
2 Biotech Stocks to Buy in May https://proinvestor.com/investornyt/1164512/2-biotech-stocks-to-buy-in-may
-
Dagens aktie er AbCellera Biologics Inc.
AbCellera Biologics bygger en motor til opdagelse og udvikling af antistoflægemidler.
Antistoffer er proteiner produceret af immunsystemet, som genkender og eliminerer mål som vira og bakterier. https://proinvestor.com/boards/120628 -
Svensk aktie i kurseksplosion efter købstilbud
"Det er Calliditas Therapeutics, der er blevet sendt på himmelflugt, efter biotekselskabet har modtaget et købstilbud. Det fremgår af en fondsbørsmeddelelse fra selskabet."
-
Zanidatamab PDUFA 26/11 i 2L BTC med priority review. https://investor.jazzpharma.com/news-releases/news-release-details/zanidatamab-granted-priority-review-her2-positive-metastatic
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind